288330 — Bridge Biotherapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Annual cashflow statement for Bridge Biotherapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	1,325	-19,232	-26,278	-41,700	-42,455
Depreciation
Amortisation
Non-Cash Items	1,345	1,206	2,949	1,415	4,819
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-10,818	4,632	1,820	-976	4,437
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-7,697	-13,037	-21,128	-40,182	-31,775
Capital Expenditures	-763	-79.8	-169	-438	-369
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-1,882	-31,774	2,123	-8,484	33,286
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Cash from Investing Activities	-2,644	-31,854	1,955	-8,922	32,917
Financing Cash Flow Items	—	-51.2	4,996	—	-1.02
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	67,270	1,859	6,026	48,643	5,086
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	56,658	-43,144	-12,743	-258	6,240